Searched for
XELPROS
Strong balance sheet, brand & management are enough to create wealth: 8 stocks with upside potential from just 2% to 32%A good stock is only good in a time frame – the time frame in which it gets you returns. A good company is one which fares well even in a d...- Sun Pharma looks to rise in US with $10 billion Organon buyIndia's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based Organon, a sp...
- Sun Pharma eyes China, Japan marketsShanghai now plans to steer the company into the specialty business (novel, innovative drugs), and towards expanding markets like China and...
- Sun Pharma makes the most of US sales: Q3 takeawaysTotal expenses increased to Rs 6,203.14 crore in the period under review.
- Sun Pharma Q3 profit jumps fourfold to Rs 1,242 crore, beats Street estimatesThe company had reported Rs 321.57 crore profit in the same quarter last year.
- Sun marches ahead with its specialty pipeline, announces European approval for TildraIn the last two months Sun Pharma has received approval for four drugs from its pipeline after a dry spell of nearly 2 years.
- Stock market update: Pharma stocks jump up to 4%; Aurobindo Pharma, Sun Pharma hog limelightThe Nifty Pharma index was trading 2.43 per cent up at 10,644 around 10:45 am.
- Sun Pharma climbs 2% on USFDA approvalThe drug in question is CEQUA (cyclosporine ophthalmic solution) 0.09 per cent.
- Sun Pharma rises with R&D and bets on specialty drugsSun Pharma- India's largest drug maker - is vying for its share in the US$9 billion market through a drug, Ilumya, that treats moderate-to-...
- Sun Pharma hits 44-month low, down 24% in 7 sessions; what experts sayThe stock fell 12.84 per cent to hit a 44-month low of Rs 495.55 amid weak fourth quarter results.
- USFDA subjects SPARC Xelpros nod to 'satisfactory resolution'Earlier this month, Sun Pharma said the US health regulator had made nine observations after the completion of inspection of its Halol faci...
- SPARC advances over 6% on getting USFDA's CRL for XelprosOn BSE, 1.14 lakh shares were traded on the counter in the first half an hour, compared with an average daily volume of 42,000 shares in th...
- Sun Pharma to buy Ocular Technologies from Auven TherapeuticsSun will pay Auven $40 million upfront, contingent development milestones and sales milestones, in addition to royalties on sales of Secier...
- USFDA nod for eyecare drug BromSite gives boost to Sun PharmaThe product will be commercialized through New Jersey-based Sun Ophthalmics, a division that Sun formed recently to route its specialty bra...
- Expect delay in start of royalty from 2 new drugs: SPARCSun Pharma Advanced Research Company (SPARC) expects further delay in start of royalty income from its two new drug applications, including...
- Sun Pharma plans to buy US-based eye care company InSite VisionSun Pharma said one of its subsidiaries plans to acquire US-based InSite Vision, a company that develops specialty ophthalmic, or eye care ...
- USFDA denies approval for SPARC's anti-glaucoma eyedropSun Pharma Advanced Research Company (SPARC) today said the US health regulator has not approved its new drug application for anti-glaucoma...
- Sensex jumps over 450 points, Cairn India rallies 12%, sugar stocks on a rollThe 30-stock Sensex opened at 26,662.75, up 201.15 points. The broader 50-share Nifty opened at 8082.15, up 60.35 points.
- Twelve stocks in focus in Wednesday's tradeIndian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.
- SPARC licenses Xelpros to Sun Pharma for US marketSun Pharma Advanced Research Company (SPARC) has licensed out Xelpros, a preservative-free eye drop, to a subsidiary of Sun Pharma for the ...
Load More
